HMGB1/GPC3 Dual Targeting Vaccine Induces Dendritic Cells-Mediated CD8+T Cell Immune Response and Elicits Potential Therapeutic Effect in Hepatocellular Carcinoma

Authors

Xiaoqing Shi
Jiage Ding
Yanyan Zheng
Jiawei Wang
Navid Sobhani
Praveen Neeli
Gang Wang
Junnian Zheng
Dafei Chai

Publication Date

2-4-2023

Journal

iScience

DOI

10.1016/j.isci.2023.106143

PMID

36879804

PMCID

PMC9984564

PubMedCentral® Posted Date

2-4-2023

PubMedCentral® Full Text Version

Post-Print

Published Open-Access

yes

Keywords

immunology, cancer

Abstract

Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment. Compared with PLGA/PEI-GPC3 immunization, PLGA/PEI-HMGB1/GPC3 co-immunization significantly inhibited the subcutaneous tumor growth, while increasing the infiltration of CD8

Comments

Associated Data